BR Biopharma, Inc. (NASDAQ:BRBI) Short Interest Update

BR Biopharma, Inc. (NASDAQ:BRBI) was the target of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 942 shares, a decrease of 96.4% from the April 15th total of 26,338 shares. Based on an average trading volume of 3,916 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings started coverage on BR Biopharma in a research report on Friday, February 13th. They set a “sell (e-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, BR Biopharma presently has a consensus rating of “Sell”.

BR Biopharma Trading Down 2.1%

Shares of BR Biopharma stock traded down $0.30 during trading hours on Monday, reaching $14.15. 2,222 shares of the company were exchanged, compared to its average volume of 4,138. BR Biopharma has a 1 year low of $12.15 and a 1 year high of $67.01. The firm has a fifty day moving average of $14.84.

BR Biopharma (NASDAQ:BRBI) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.09 earnings per share for the quarter. The business had revenue of $25.95 million during the quarter.

BR Biopharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Tuesday, May 19th will be paid a $0.147 dividend. The ex-dividend date is Tuesday, May 19th. This represents a $0.59 dividend on an annualized basis and a yield of 4.2%.

Institutional Trading of BR Biopharma

A hedge fund recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC purchased a new stake in BR Biopharma, Inc. (NASDAQ:BRBI) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma makes up about 3.2% of Acuitas Investments LLC’s holdings, making the stock its 7th largest position.

About BR Biopharma

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.